scispace - formally typeset
M

Masato Nakaguro

Researcher at Nagoya University

Publications -  70
Citations -  839

Masato Nakaguro is an academic researcher from Nagoya University. The author has contributed to research in topics: Medicine & Adenocarcinoma. The author has an hindex of 11, co-authored 57 publications receiving 375 citations. Previous affiliations of Masato Nakaguro include Harvard University.

Papers
More filters
Proceedings ArticleDOI

Multi-scale Domain-adversarial Multiple-instance CNN for Cancer Subtype Classification with Unannotated Histopathological Images

TL;DR: Wang et al. as mentioned in this paper proposed a method for cancer subtype classification from histopathological images, which can automatically detect tumor-specific features in a given whole slide image (WSI), i.e., a large-sized image (typically 40,000x40,000 pixels) of an entire pathological tissue slide, which consists of cancer and non-cancer portions.
Posted Content

Multi-scale Domain-adversarial Multiple-instance CNN for Cancer Subtype Classification with Unannotated Histopathological Images

TL;DR: A new CNN-based cancer subtype classification method is developed by effectively combining multiple-instance, domain adversarial, and multi-scale learning frameworks in order to overcome practical difficulties.
Journal ArticleDOI

The Neuronal Differentiation Factor NeuroD1 Downregulates the Neuronal Repellent Factor Slit2 Expression and Promotes Cell Motility and Tumor Formation of Neuroblastoma

TL;DR: The findings establish the critical role of the neuronal differentiation factor NeuroD1 in neuroblastoma as well as its functional relationship with the neuronal repellent factor Slit2 and the functions identified for NeuroD 1 in cell motility and tumor sphere growth.
Journal ArticleDOI

Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.

TL;DR: This case showed that even if at a late phase, long-term use of immune checkpoint inhibitors might to lead immune-related adverse events including myocarditis, and nivolumab therapy rarely occurred at > 2 months use in clinical trials.
Journal ArticleDOI

Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment

TL;DR: Several clinical studies have shown promising results using targeted therapy for androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2), and the latest version of the National Comprehensive Cancer Network guidelines recommends the evaluation of AR and HER2 status before treatment.